12 recruiting, 3 active not recruiting, 1 not yet recruiting, 1 terminated. 18 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Recruiting 12, Active not recruiting 3, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Recruiting 2, Withdrawn 1 |
Follow Tarlatamab: new trials by email Literature Review of Tarlatamab trials Research Report on Tarlatamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer ABBV-706, Tarlatamab, Atezolizumab - Extensive Stage-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | AbbVie | 80 | 2026-11-04 | 2026-10-26 |
| Tarlatamab for SCLC Brain Metastases Tarlatamab - Small Cell Lung Cancer, Brain Metastases, Adult | Phase 2 | Recruiting | Maastricht University Medical Center | 35 | 2026-08-10 | 2026-10-28 |
| Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients Tarlatamab - Limited-stage Small-cell Lung Cancer, Carcinoma, Small Cell Lung | Phase 2 | Recruiting | Fundación GECP | 37 | 2026-05-20 | 2026-07-08 |
| Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer Tarlatamab, Sacituzumab Govitecan - Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-04-25 | 2026-04-28 | |
| A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2 Tarlatamab - Extensive Stage Lung Small Cell Cancer | Phase 2 | Recruiting | ETOP IBCSG Partners Foundation | 48 | 2026-04-15 | 2026-09-21 |
| Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma | Phase 2 | Recruiting | Asrar Alahmadi | 39 | 2026-03-20 | 2026-07-06 |
| Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS) Tarlatamab - Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma | Phase 2 | Recruiting | National Taiwan University Hospital | 32 | 2026-01-01 | 2026-09-17 |
| Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab Tarlatamab, standard of care second-line chemotherapy (FOLFIRI) - Advanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin | Phase 2 | Terminated | Grupo Espanol de Tumores Neuroendocrinos | 1 | 2025-12-18 | 2026-09-18 |
| Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors Tarlatamab, Temozolomide (TMZ) - Glioma, CNS Tumor, Adult | Phase 1 / Phase 2 | Recruiting | Centre Leon Berard | 70 | 2025-11-04 | 2026-09-14 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients Tarlatamab - Neuroendocrine Carcinomas (NEC), Neuroendocrine Carcinoma of Pancreas | Phase 2 | Recruiting | Inkeun Park | 60 | 2025-09-02 | 2026-04-13 |
| Study of How Safe and Effective Tarlatamab is in Brain Cancers Tarlatamab - Astrocytic Tumor, Oligodendroglial Tumor | Phase 2 | Recruiting | University Health Network, Toronto | 44 | 2025-08-18 | 2025-09-19 |
| A Study of Tarlatamab for People With Prostate Cancer Tarlatamab - Metastatic Prostate Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 32 | 2025-07-31 | 2026-08-31 |
| Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) Tarlatamab - Metastatic/Locally Advanced Small-Cell Lung Cancer, Metastatic/Locally Advanced Poorly Differentiated NEC | Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 40 | 2025-07-02 | 2026-09-09 |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC Tarlatamab - Small Cell Lung Cancer (SCLC) | Phase 2 | Active not recruiting | Amgen | 252 | 2025-02-26 | 2026-10-06 |
| Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status Tarlatamab - Small-cell Lung Cancer | Phase 2 | Recruiting | AIO-Studien-gGmbH | 57 | 2025-01-01 | 2026-10-26 |
| Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment Tarlatamab - Extensive Stage Small Cell Lung Cancer | Phase 2 | Active not recruiting | Amgen | 32 | 2024-08-27 | 2026-10-21 |
| A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) Tarlatamab - Relapsed/Refractory Small Cell Lung Cancer | Phase 2 | Active not recruiting | Amgen | 222 | 2021-12-01 | 2026-07-22 |
Small Cell Lung Carcinoma (7) · Carcinoma, Neuroendocrine (2) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Medullary (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Small Cell (1) · Central Nervous System Neoplasms (1) · Esthesioneuroblastoma, Olfactory (1) · Glioblastoma (1) · Glioma (1) · Melanoma (1) · Neoplasm Metastasis (1)
Amgen (3) · AIO-Studien-gGmbH (1) · AbbVie (1) · Asrar Alahmadi (1) · Centre Leon Berard (1) · ETOP IBCSG Partners Foundation (1) · Fundación GECP (1) · Grupo Espanol de Tumores Neuroendocrinos (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Inkeun Park (1) · Maastricht University Medical Center (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1) · National Taiwan University Hospital (1) · University Health Network, Toronto (1)
France (6) · United States (6) · Spain (5) · Germany (3) · Greece (3) · Italy (3) · South Korea (3) · Switzerland (3) · Belgium (2) · China (2) · Japan (2) · Netherlands (2) · Taiwan (2) · United Kingdom (2) · Argentina (1)
Anish Thomas, M.D. (1) · Asrar AlAhmadi, MBBS (1) · Charles Hsu, MD (1) · Eric Chen, MD (1) · Federico Capuzzo, MD (1) · Inkeun Park, M.D, Ph D (1) · Jaume Capdevila, M.D., Ph.D. (1) · Karen Autio, MD (1) · Mariano Provencio, MD (1) · Ricklie Julian, MD (1)
PMID 12675312, PMID 13680158, PMID 15173079, PMID 16200343, PMID 16530701, PMID 16786120, PMID 16899365, PMID 17664336, PMID 17705175, PMID 18509186, PMID 19221744, PMID 20167817, PMID 20838435, PMID 21147753, PMID 21150307, PMID 21327941, PMID 22665268, PMID 23243055, PMID 25856312, PMID 26311731, PMID 26545842, PMID 27006176, PMID 27230974, PMID 27247755, PMID 27782828, PMID 28439777, PMID 29412784, PMID 30397180, PMID 33123732, PMID 33713320, PMID 33754151, PMID 33921457, PMID 34185076, PMID 34261630, PMID 3470008, PMID 34795007, PMID 35124175, PMID 35332121, PMID 35567713, PMID 36090479, PMID 36362482, PMID 36689692, PMID 37861218, PMID 9189180
2025 (2), 2023 (1)